Welcome to the HBV Advocate’s DDW Conference coverage. In an effort to best serve our readership, we will post all the important and interesting abstracts about HBV from the conference. While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted. The other abstracts posted to the web site are HBV related abstracts posted to www.ddw.org that we have not been able to report on or update.

To locate specific abstracts for each topic below, click on the links.

Please click here to view our fact sheet on reading and understanding an abstract.

Thank You,

Alan Franciscus

Editor-in-Chief

Hepatitis B

· Diagnostic Tools

o 585. Elevated levels of circulating mesenchymal stem cells in patients with chronic hepatitis B and C

o S1226. Diagnostic value of biochemical markers for prediction of liver fibrosis and inflammation in pediatric patients.

o S1340. Clinical Predictors for Recurrence of Esophageal Varices after Obliteration by Endoscopic Band Ligation

o S1765. Changes in Serum Alanine Aminotransferase (ALT) Level Using a Trajectory Model and Risk of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB): The R.E.V.E.A.L.-HBV Study

o T1084. Elevated Serum Alanine Aminotransferase (ALT) Activity Does Not Increase Cardiovascular Disease (CVD) Mortality in the United States Population

· Disease Progression

o 90. HBV replication can be controlled through TLR-induced production of IFN-beta by non-parenchymal liver cells

o 91. Prognosis following hepatitis B surface antigen seroclearance: a systematic review of 9 cohort studies and 1398 patients.

o 94. Presence of Biopsy-Proven Histologic Damage (Necroinflammation And Fibrosis) is Common Even When ALT is Less Than 2X ULN in Patients With Chronic Hepatitis B (CHB)

o 588. Correlation of hepatic fibrosis with serum ALT and viral levels in patient with chronic hepatitis B

o 590. Age Greater that 40 is a Stronger Predictor of Advanced Chronic Hepatitis B (HBV) than Current North American HBV Treatment Algorithms That Demonstrate Low Predictive Value Regardless of HBeAg, Viral Load, or Alanine Aminotransferase (ALT).

o M1842. Transient elastography in chronic hepatitis B and C predicts severe fibrosis similarly

o S1758. Causes of Death Associated With Hepatitis B or Hepatitis C Virus Infections in a Long-Term Population-Based Cohort Study

o Portal Hypertension

§ T1039. Impact of prophylactic antibiotics in cirrhotic patients presenting with sepsis.

§ T1043. Endoscopic Band Ligation May Not Be Inferior to Endoscopic Injection Sclerotheraphy in Cardiac Variceal Bleeding, Not Fundal Variceal Bleeding

o Steatohepatitisi

§ 513. Associate Factors Of Nonalcoholic Fatty Liver Disease : Results From A Population-Based Study.

§ S2158. Prevalence and associated factors of nonalcoholic liver fatty disease and metabolic syndrome: results from a cross-sectional study

§ T1064. Health Utility Assessment Using SF-6D and Health Utility Index (HUI) in Patients with Chronic Viral Hepatitis and Non-alcoholic Fatty Liver Disaese (NAFLD)

· Epidemiology

o M1015. Rates and Predictors of Depression in an Out-patient Hepatology Practice

o S1055. Comorbid Medical and Psychiatric Illness and Substance Abuse in HCV-Infected and Uninfected Veterans

o S1227. Prevalence and risk factors associated with hepatitis B and hepatitis C virus infections among healthy population in an urban community in Dhaka, Bangladesh

o S1771. Hepatitis B Patient Survey: Disease Understanding and Compliance in the United States

o S1775. A Survey of Hepatitis B Patient Demographics, Disease Characteristics and Management Practice in the United States.

o W1044. Digestive Diseases in the Native American Population of the U.S. Central Plains: Disparities in Prevalence, Screening, and Treatment

· General

o S1778. Hepatitis B Prophylaxis in Patients Undergoing Chemotherapy for Lymphoma: A Decision Analysis Model.

· HBV & Liver Transplantation

o S1728. The Prevalence and Significance of Occult Hepatitis B In A Liver Transplant population with Chronic Hepatitis C.

o S1730. Beneficial effects of Short-Term Lamivudine Treatment for de novo Hepatitis B Virus Reactivation After Liver Transplantation.

o S1779. Prevention Of Hepatitis B Reactivation In Hepatitis B Surface Antigen (Hbsag) Negative Liver Transplant Recipients From Hepatitis B Core Antibody (Anti-Hbc) Positive Grafts With Lamivudine Monotherapy

· Immune Response

o 280. The Envelope Protein of the Hepatitis C virus (E2) inhibits IL-2 Secretion from T lymphocytes

· Liver Cancer

o S1736. Impact of Extended Criteria Donor Livers on Survival of Patients with Hepatocellular Carcinoma.

o S1766. A Risk Function Nomogram for Predicting HCC in Patients With Chronic Hepatitis B: The R.E.V.E.A.L.-HBV Study

· Treatment

o Antiviral Treatments for Hepatitis B

§ 95. Tenofovir (TDF) monotherapy is effective in suppressing serum HBV DNA in chronic hepatitis B (CHB) patients with primary nonresponse to adefovir (ADV) but not those with ADV-resistant HBV.

§ S1230. Sequential Treatment With Lamivudine And Alpha-Interferon In Chronic Hepatitis B: A Pilot Study.

§ S1767. Lamivudine Prophylaxis is Effective in Reducing Reactivation and Reactivation Related Liver Mortality: A Meta-Analysis

§ S1768. A Phase III Comparative Trial of Telbivudine vs Lamivudine in Chinese Patients with Chronic Hepatitis B: Two-Year Results.

§ S1770. Prophylactic Lamivudine for Prevention of Chemotherapy-induced Hepatitis B Virus Reactivation: Meta-analysis of Clinical Trials

§ S1773. Entecavir (ETV) Results in Higher HBV-DNA Reduction vs Adefovir (ADV) In Chronically Infected HBeAg(+) Antiviral-Naive Adults: 48-Week Results (E.A.R.L.Y. STUDY).

§ S1774. A Randomized Trial of Telbivudine vs Adefovir for HBeAg-Positive Chronic Hepatitis B: Efficacy Through Week 76, Predictors of Response and Effects of Switching to Telbivudine

§ S1776. Salvage Therapy with Adefovir for Virologic Breakthrough in Telbivudine-Treated Patients from the GLOBE Study

§ S1777. Telbivudine Globe Trial at Year Two: Efficacy, Safety, and Predictors of Outcome in Patients with Chronic Hepatitis B.

§ S1781. Resistance Determination in Patients Experiencing Virologic Breakthrough Following Telbivudine or Lamivudine Therapy in the International GLOBE Trial.

§ S1782. Absence of Pharmacokinetic Drug-Drug Interaction Between Telbivudine and Tenofovir

o Genotypes

§ 93. Genotypic Analysis of Patients with Evaluable HBV DNA After 1 Year of Telbivudine Therapy in the GLOBE Registration Trial.

§ S1783. Cross Trial Comparison of Genotypic Response Rates with Adefovir, Entecavir or Telbivudine for Chronic Hepatitis B